Last reviewed · How we verify
HPV9 Low formulation — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
HPV9 Low formulation (HPV9 Low formulation) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HPV9 Low formulation TARGET | HPV9 Low formulation | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HPV9 Low formulation CI watch — RSS
- HPV9 Low formulation CI watch — Atom
- HPV9 Low formulation CI watch — JSON
- HPV9 Low formulation alone — RSS
Cite this brief
Drug Landscape (2026). HPV9 Low formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/hpv9-low-formulation. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab